Picture of Mesa Laboratories logo

MLAB — Mesa Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Mesa Laboratories Q2 revenue rises on divisional performance

Mesa Laboratories Q2 revenue rises on divisional performance


Overview

  • Life sciences tools maker's fiscal Q2 revenue rose 2.6% yr/yr

  • EPS for fiscal Q2 was $0.75, net income climbed 75% yr/yr

  • Company authorized new $40 mln share repurchase program


Outlook

  • Mesa Labs sees FY27 revenues of $250 mln to $255 mln

  • Company expects FY27 adjusted EBITDA of $66 mln to $68 mln

  • Company expects Q3 revenues to be flat year-over-year, mainly due to lower Clinical Genomics


Result Drivers

  • DIVISIONAL PERFORMANCE - Revenue growth was led by Sterilization and Disinfection Control and Calibration Solutions, while Biopharmaceutical Development declined

  • PRODUCTION RECOVERY - Resolved production issues in Sterilization and Disinfection Control led to higher shipments and revenue growth

  • EXPORT-CONTROL DELAYS - Biopharmaceutical Development revenues fell due to export-control processing delays impacting peptide hardware sales


Company press release: ID:nGNX8XP3Lz


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Slight Beat*

$62.34 mln

$62.20 mln (2 Analysts)

Q2 EPS

$0.75

Q2 Net Income

$4.34 mln

Q2 Basic EPS

$0.77

Q2 Gross Profit

$39.88 mln

Q2 Operating Expenses

$31.49 mln

Q2 Operating Income

$8.39 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Mesa Laboratories, Inc. is $125.00, about 2.5% below its November 6 closing price of $128.25

  • The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 62 three months ago


Reuters Recommended Reads

  • Nov 9 - Quanterix Q3 revenue rises 6.3% sequentially

  • Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves

  • Nov 9 - Hyperfine Q3 revenue jumps on higher system sales; net loss narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Mesa Laboratories

See all news